Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$56.44

0.08 (0.14%)

07:41
12/01/16
12/01
07:41
12/01/16
07:41

Bristol-Myers price target lowered to $85 from $100 at Cowen

Cowen analyst Steve Scala lowered his price target on Bristol-Myers to $85 from $100 due to the increased competition in the PD-1/PD-L1 area. However, following a meeting with management the analyst came away with stronger conviction in both the company's strategy and pipeline. Scala maintained his Buy rating on Bristol-Myers shares.

  • 01

    Dec

  • 03

    Dec

BMY Bristol-Myers
$56.44

0.08 (0.14%)

10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.

TODAY'S FREE FLY STORIES

FEYE

FireEye

11:45
06/27/17
06/27
11:45
06/27/17
11:45
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

11:45
06/27/17
06/27
11:45
06/27/17
11:45
General news
Treasury's $40 B 4-week bill sale was poorly subscribed »

Treasury's $40 B…

BT

BT Group

$18.68

0.06 (0.32%)

11:42
06/27/17
06/27
11:42
06/27/17
11:42
Upgrade
BT Group rating change  »

BT Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
06/27/17
06/27
11:35
06/27/17
11:35
General news
Treasury Option Action: a round of call buying in the belly »

Treasury Option Action: a…

OSUR

OraSure

$15.72

0.17 (1.09%)

11:31
06/27/17
06/27
11:31
06/27/17
11:31
Recommendations
OraSure analyst commentary  »

OraSure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

XLF

Financial Select Sector

$24.19

0.17 (0.71%)

11:30
06/27/17
06/27
11:30
06/27/17
11:30
Options
SPDR Financial calls outpace puts nearly 25:1 »

SPDR Financial calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KITE

Kite Pharma

$100.43

-0.23 (-0.23%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Options
Kite Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

ANY

Sphere 3D

$0.20

0.0275 (16.08%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Conference/Events
Sphere 3D to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MRK

Merck

$66.14

0.215 (0.33%)

11:20
06/27/17
06/27
11:20
06/27/17
11:20
Periodicals
Merck confirms computer network 'compromised' by global hack »

Merck stated in a series…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

11:20
06/27/17
06/27
11:20
06/27/17
11:20
General news
Fed's Harker still backs another rate hike this year »

Fed's Harker still…

BLK

BlackRock

$425.20

0.51 (0.12%)

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Hot Stocks
BlackRock to acquire Cachematrix »

BlackRock has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/27/17
06/27
11:16
06/27/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/27/17
06/27
11:15
06/27/17
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

PSX

Phillips 66

$80.96

0.72 (0.90%)

, CVX

Chevron

$104.76

0.62 (0.60%)

11:11
06/27/17
06/27
11:11
06/27/17
11:11
Hot Stocks
Chevron Phillips Chemical names Mark Lashier CEO »

Chevron Phillips Chemical…

PSX

Phillips 66

$80.96

0.72 (0.90%)

CVX

Chevron

$104.76

0.62 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

11:10
06/27/17
06/27
11:10
06/27/17
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

ALDR

Alder Biopharmaceuticals

$18.70

-1 (-5.08%)

11:03
06/27/17
06/27
11:03
06/27/17
11:03
Recommendations
Alder Biopharmaceuticals analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AA

Alcoa

$32.33

1.15 (3.69%)

11:00
06/27/17
06/27
11:00
06/27/17
11:00
Options
Alcoa attracts call buying »

Alcoa attracts call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
Breaking General news story  »

Philadelphia Federal…

HCC

Warrior Met Coal

$15.88

-0.31 (-1.91%)

10:58
06/27/17
06/27
10:58
06/27/17
10:58
Downgrade
Warrior Met Coal rating change  »

Follow-up: Warrior Met…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

Bazaarvoice

$4.80

-0.1 (-2.04%)

10:56
06/27/17
06/27
10:56
06/27/17
10:56
Conference/Events
Bazaarvoice management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CBI

CB&I

$16.50

2.1 (14.58%)

, TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Periodicals
Court rules for Chicago Bridge in Westinghouse case, Reuters says »

The Delaware Supreme…

CBI

CB&I

$16.50

2.1 (14.58%)

TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

TOSYY

Toshiba, also use TOSBF

$15.91

-0.065 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks on economic outlook »

Philadelphia Federal…

LTRX

Lantronix

$2.37

-0.08 (-3.27%)

10:54
06/27/17
06/27
10:54
06/27/17
10:54
Conference/Events
Lantronix management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.